Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EPS (Basic) (2022 - 2026)

Sagimet Biosciences' EPS (Basic) history spans 5 years, with the latest figure at -$0.33 for Q1 2026.

  • Quarterly EPS (Basic) rose 41.07% to -$0.33 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.35 through Mar 2026, up 23.3% year-over-year, with the annual reading at -$1.58 for FY2025, 8.97% down from the prior year.
  • EPS (Basic) came in at -$0.33 for Q1 2026, down from -$0.3 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.56 in Q4 2023 to a low of -$40.34 in Q3 2022.
  • The 5-year median for EPS (Basic) is -$0.43 (2024), against an average of -$12.02.
  • Year-over-year, EPS (Basic) surged 101.43% in 2023 and then plummeted 189.29% in 2024.
  • Sagimet Biosciences' EPS (Basic) stood at -$39.07 in 2022, then soared by 101.43% to $0.56 in 2023, then tumbled by 189.29% to -$0.5 in 2024, then skyrocketed by 40.0% to -$0.3 in 2025, then decreased by 10.0% to -$0.33 in 2026.
  • Per Business Quant, the three most recent readings for SGMT's EPS (Basic) are -$0.33 (Q1 2026), -$0.3 (Q4 2025), and -$0.4 (Q3 2025).